Health Care–Associated Infections: A Meta-analysis of Costs and Financial Impact on the US Health Care System | Critical Care Medicine | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Kohn  LT, Corrigan  JM, Donaldson  MS.  To Err Is Human: Building a Safer Health System. Washington, DC: National Academies Press; 1999.
2.
Leape  LL, Brennan  TA, Laird  N,  et al.  The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II.  N Engl J Med. 1991;324(6):377-384.PubMedGoogle ScholarCrossref
3.
Klevens  RM, Edwards  JR, Richards  CL  Jr,  et al.  Estimating health care-associated infections and deaths in US hospitals, 2002.  Public Health Rep. 2007;122(2):160-166.PubMedGoogle Scholar
4.
Yokoe  DS, Mermel  LA, Anderson  DJ,  et al.  A compendium of strategies to prevent healthcare-associated infections in acute care hospitals.  Infect Control Hosp Epidemiol. 2008;29(suppl 1):S12-S21.PubMedGoogle ScholarCrossref
5.
Centers for Disease Control and Prevention. Making health care safer: reducing bloodstream infections. http://www.cdc.gov/VitalSigns/pdf/2011-03-vitalsigns.pdf. Accessed September 1, 2012.
6.
Pronovost  P, Needham  D, Berenholtz  S,  et al.  An intervention to decrease catheter-related bloodstream infections in the ICU.  N Engl J Med. 2006;355(26):2725-2732.PubMedGoogle ScholarCrossref
7.
National Quality Forum. Safe practices for better healthcare: 2010 update. http://www.qualityforum.org/Projects/Safe_Practices_2010.aspx. Accessed September 14, 2012.
8.
Umscheid  CA, Mitchell  MD, Doshi  JA, Agarwal  R, Williams  K, Brennan  PJ.  Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs.  Infect Control Hosp Epidemiol. 2011;32(2):101-114.PubMedGoogle ScholarCrossref
9.
Jha  AK, Chan  DC, Ridgway  AB, Franz  C, Bates  DW.  Improving safety and eliminating redundant tests: cutting costs in US hospitals.  Health Aff (Millwood). 2009;28(5):1475-1484.PubMedGoogle ScholarCrossref
10.
Rosenthal  MB.  Nonpayment for performance? Medicare’s new reimbursement rule.  N Engl J Med. 2007;357(16):1573-1575.PubMedGoogle ScholarCrossref
11.
Department of Health and Human Services; Centers for Medicare & Medicaid Services. Medicaid program: payment adjustment for provider-preventable conditions including health care-acquired conditions. www.gpo.gov/fdsys/pkg/FR-2011-06-06/pdf/2011-13819.pdf‎. Accessed July 24, 2013.
12.
Ranji  SR, Shetty  K, Posley  KA,  et al.  Prevention of Healthcare-Associated Infections: AHRQ Publication 04(07)-0051-6. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
13.
Berger  S.  Fundamentals of Healthcare Financial Issues and Activities. San Francisco, CA: John Wiley and Sons, Inc; 2008.
14.
Producer Price Index. Industry Data, General medical and surgical hospitals (series PCU62211-62211-) http://www.bls.gov/ppi/home.htm. Accessed August 9, 2013.
15.
Borenstein  M, Hedges  LV, Higgins  JPT, Rothstein  HR.  A basic introduction to fixed-effect and random-effects models for meta-analysis.  Res Synth Method. 2010;1:97-111.Google ScholarCrossref
16.
Buckland  ST.  Monte Carlo confidence intervals.  Biometrics. 1984;40(3):811-817.Google ScholarCrossref
17.
Sun  X, Faunce  T.  Decision-analytical modelling in health-care economic evaluations.  Eur J Health Econ. 2008;9(4):313-323.PubMedGoogle ScholarCrossref
18.
Agency for Healthcare Research and Quality. NIS overview. http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed September 14, 2012.
19.
Dudeck  MA, Horan  TC, Peterson  KD,  et al.  National Healthcare Safety Network (NHSN) report, data summary for 2009, device-associated module.  Am J Infect Control. 2011;39(5):349-367.PubMedGoogle ScholarCrossref
20.
Srinivasan  A, Wise  M, Bell  M,  et al; Centers for Disease Control and Prevention (CDC).  Vital signs: central line-associated blood stream infections—United States, 2001, 2008, and 2009.  MMWR Morb Mortal Wkly Rep. 2011;60(8):243-248.PubMedGoogle Scholar
21.
Kirkland  KB, Briggs  JP, Trivette  SL, Wilkinson  WE, Sexton  DJ.  The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs.  Infect Control Hosp Epidemiol. 1999;20(11):725-730.PubMedGoogle ScholarCrossref
22.
Dimick  JB, Pronovost  PJ, Cowan  JA, Lipsett  PA.  Complications and costs after high-risk surgery: where should we focus quality improvement initiatives?  J Am Coll Surg. 2003;196(5):671-678.PubMedGoogle ScholarCrossref
23.
Kaye  KS, Anderson  DJ, Sloane  R,  et al.  The effect of surgical site infection on older operative patients.  J Am Geriatr Soc. 2009;57(1):46-54.PubMedGoogle ScholarCrossref
24.
Eagye  KJ, Nicolau  DP.  Deep and organ/space infections in patients undergoing elective colorectal surgery: incidence and impact on hospital length of stay and costs.  Am J Surg. 2009;198(3):359-367.PubMedGoogle ScholarCrossref
25.
Apisarnthanarak  A, Jones  M, Waterman  BM, Carroll  CM, Bernardi  R, Fraser  VJ.  Risk factors for spinal surgical-site infections in a community hospital: a case-control study.  Infect Control Hosp Epidemiol. 2003;24(1):31-36.PubMedGoogle ScholarCrossref
26.
Whitehouse  JD, Friedman  ND, Kirkland  KB, Richardson  WJ, Sexton  DJ.  The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost.  Infect Control Hosp Epidemiol. 2002;23(4):183-189.PubMedGoogle ScholarCrossref
27.
Hollenbeak  CS, Murphy  DM, Koenig  S, Woodward  RS, Dunagan  WC, Fraser  VJ.  The clinical and economic impact of deep chest surgical site infections following coronary artery bypass graft surgery.  Chest. 2000;118(2):397-402.PubMedGoogle ScholarCrossref
28.
de Lissovoy  G, Fraeman  K, Hutchins  V, Murphy  D, Song  D, Vaughn  BB.  Surgical site infection: incidence and impact on hospital utilization and treatment costs.  Am J Infect Control. 2009;37(5):387-397.PubMedGoogle ScholarCrossref
29.
Olsen  MA, Mayfield  J, Lauryssen  C,  et al.  Risk factors for surgical site infection in spinal surgery.  J Neurosurg. 2003;98(2)(suppl):149-155.PubMedGoogle Scholar
30.
Olsen  MA, Chu-Ongsakul  S, Brandt  KE, Dietz  JR, Mayfield  J, Fraser  VJ.  Hospital-associated costs due to surgical site infection after breast surgery.  Arch Surg. 2008;143(1):53-61.PubMedGoogle ScholarCrossref
31.
Olsen  MA, Butler  AM, Willers  DM, Gross  GA, Hamilton  BH, Fraser  VJ.  Attributable costs of surgical site infection and endometritis after low transverse cesarean delivery.  Infect Control Hosp Epidemiol. 2010;31(3):276-282.PubMedGoogle ScholarCrossref
32.
Toumpoulis  IK, Anagnostopoulos  CE, Derose  JJ  Jr, Swistel  DG.  The impact of deep sternal wound infection on long-term survival after coronary artery bypass grafting.  Chest. 2005;127(2):464-471.PubMedGoogle ScholarCrossref
33.
Anderson  DJ, Kaye  KS, Chen  LF,  et al.  Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study.  PLoS One. 2009;4(12):e8305.PubMedGoogle ScholarCrossref
34.
Warren  DK, Quadir  WW, Hollenbeak  CS, Elward  AM, Cox  MJ, Fraser  VJ.  Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital.  Crit Care Med. 2006;34(8):2084-2089.PubMedGoogle ScholarCrossref
35.
Digiovine  B, Chenoweth  C, Watts  C, Higgins  M.  The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit.  Am J Respir Crit Care Med. 1999;160(3):976-981.PubMedGoogle ScholarCrossref
36.
Pittet  D, Tarara  D, Wenzel  RP.  Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality.  JAMA. 1994;271(20):1598-1601.PubMedGoogle ScholarCrossref
37.
Dimick  JB, Pelz  RK, Consunji  R, Swoboda  SM, Hendrix  CW, Lipsett  PA.  Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit.  Arch Surg. 2001;136(2):229-234.PubMedGoogle ScholarCrossref
38.
Abramson  MA, Sexton  DJ.  Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?  Infect Control Hosp Epidemiol. 1999;20(6):408-411.PubMedGoogle ScholarCrossref
39.
Kollef  MH, Hamilton  CW, Ernst  FR.  Economic impact of ventilator-associated pneumonia in a large matched cohort.  Infect Control Hosp Epidemiol. 2012;33(3):250-256.PubMedGoogle ScholarCrossref
40.
Restrepo  MI, Anzueto  A, Arroliga  AC,  et al.  Economic burden of ventilator-associated pneumonia based on total resource utilization.  Infect Control Hosp Epidemiol. 2010;31(5):509-515.PubMedGoogle ScholarCrossref
41.
Warren  DK, Shukla  SJ, Olsen  MA,  et al.  Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.  Crit Care Med. 2003;31(5):1312-1317.PubMedGoogle ScholarCrossref
42.
Rello  J, Ollendorf  DA, Oster  G,  et al; VAP Outcomes Scientific Advisory Group.  Epidemiology and outcomes of ventilator-associated pneumonia in a large US database.  Chest. 2002;122(6):2115-2121.PubMedGoogle ScholarCrossref
43.
Kyne  L, Hamel  MB, Polavaram  R, Kelly  CP.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile Clin Infect Dis. 2002;34(3):346-353.PubMedGoogle ScholarCrossref
44.
O’Brien  JA, Lahue  BJ, Caro  JJ, Davidson  DM.  The emerging infectious challenge of Clostridium difficile–associated disease in Massachusetts hospitals: clinical and economic consequences.  Infect Control Hosp Epidemiol. 2007;28(11):1219-1227.PubMedGoogle ScholarCrossref
45.
Lai  KK, Fontecchio  SA.  Use of silver-hydrogel urinary catheters on the incidence of catheter-associated urinary tract infections in hospitalized patients.  Am J Infect Control. 2002;30(4):221-225.PubMedGoogle ScholarCrossref
46.
Tambyah  PA, Knasinski  V, Maki  DG.  The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care.  Infect Control Hosp Epidemiol. 2002;23(1):27-31.PubMedGoogle ScholarCrossref
47.
Jarvis  WR, Schlosser  J, Jarvis  AA, Chinn  RY.  National point prevalence of Clostridium difficile in US health care facility inpatients, 2008.  Am J Infect Control. 2009;37(4):263-270.PubMedGoogle ScholarCrossref
48.
McDonald  LC, Owings  M, Jernigan  DB.  Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.  Emerg Infect Dis. 2006;12(3):409-415.PubMedGoogle Scholar
49.
Ricciardi  R, Rothenberger  DA, Madoff  RD, Baxter  NN.  Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States.  Arch Surg. 2007;142(7):624-631.PubMedGoogle ScholarCrossref
50.
Scott DR; Center for Disease Control and Prevention. The direct medical costs of healthcare-associated infections in US hospitals and the benefits of prevention. http://www.cdc.gov/HAI/pdfs/hai/Scott_CostPaper.pdf. Accessed September 1, 2012.
51.
Kallen  AJ, Mu  Y, Bulens  S,  et al; Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program.  Health care-associated invasive MRSA infections, 2005-2008.  JAMA. 2010;304(6):641-648.PubMedGoogle ScholarCrossref
52.
Landrigan  CP, Parry  GJ, Bones  CB, Hackbarth  AD, Goldmann  DA, Sharek  PJ.  Temporal trends in rates of patient harm resulting from medical care.  N Engl J Med. 2010;363(22):2124-2134.PubMedGoogle ScholarCrossref
53.
Centers for Medicare and Medicaid Services. Hospital-acquired conditions (HAC) in acute inpatient prospective payment system (IPPS) hospitals fact sheet, 2011. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/downloads/HACFactsheet.pdf. Accessed July 24, 2013.
54.
McNair  PD, Luft  HS, Bindman  AB.  Medicare’s policy not to pay for treating hospital-acquired conditions: the impact.  Health Aff (Millwood). 2009;28(5):1485-1493.PubMedGoogle ScholarCrossref
Original Investigation
December 9/23, 2013

Health Care–Associated Infections: A Meta-analysis of Costs and Financial Impact on the US Health Care System

Author Affiliations
  • 1Division of General Internal Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Sheba Medical Center, Ramat-Gan, Israel
  • 3Eastern Research Group, Lexington, Massachusetts
  • 4Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio
  • 5Controlled Risk Insurance Company, Cambridge, Massachusetts
  • 6Texas Medical Institute of Technology, Austin
  • 7Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts
JAMA Intern Med. 2013;173(22):2039-2046. doi:10.1001/jamainternmed.2013.9763
Abstract

Importance  Health care–associated infections (HAIs) account for a large proportion of the harms caused by health care and are associated with high costs. Better evaluation of the costs of these infections could help providers and payers to justify investing in prevention.

Objective  To estimate costs associated with the most significant and targetable HAIs.

Data Sources  For estimation of attributable costs, we conducted a systematic review of the literature using PubMed for the years 1986 through April 2013. For HAI incidence estimates, we used the National Healthcare Safety Network of the Centers for Disease Control and Prevention (CDC).

Study Selection  Studies performed outside the United States were excluded. Inclusion criteria included a robust method of comparison using a matched control group or an appropriate regression strategy, generalizable populations typical of inpatient wards and critical care units, methodologic consistency with CDC definitions, and soundness of handling economic outcomes.

Data Extraction and Synthesis  Three review cycles were completed, with the final iteration carried out from July 2011 to April 2013. Selected publications underwent a secondary review by the research team.

Main Outcomes and Measures  Costs, inflated to 2012 US dollars.

Results  Using Monte Carlo simulation, we generated point estimates and 95% CIs for attributable costs and length of hospital stay. On a per-case basis, central line–associated bloodstream infections were found to be the most costly HAIs at $45 814 (95% CI, $30 919-$65 245), followed by ventilator-associated pneumonia at $40 144 (95% CI, $36 286-$44 220), surgical site infections at $20 785 (95% CI, $18 902-$22 667), Clostridium difficile infection at $11 285 (95% CI, $9118-$13 574), and catheter-associated urinary tract infections at $896 (95% CI, $603-$1189). The total annual costs for the 5 major infections were $9.8 billion (95% CI, $8.3-$11.5 billion), with surgical site infections contributing the most to overall costs (33.7% of the total), followed by ventilator-associated pneumonia (31.6%), central line–associated bloodstream infections (18.9%), C difficile infections (15.4%), and catheter-associated urinary tract infections (<1%).

Conclusions and Relevance  While quality improvement initiatives have decreased HAI incidence and costs, much more remains to be done. As hospitals realize savings from prevention of these complications under payment reforms, they may be more likely to invest in such strategies.

×